NasdaqGS:IMVTBiotechs
Should Batoclimab’s Phase 3 Miss in Thyroid Eye Disease Require Action From Immunovant (IMVT) Investors?
In April 2026, Immunovant reported that two Phase 3 GO studies of its FcRn inhibitor batoclimab in adults with active, moderate-to-severe thyroid eye disease did not meet the pre-specified primary endpoint of ≥2mm proptosis response at Week 24, though safety findings remained consistent and no new signals emerged.
The data suggested stronger proptosis improvements during the initial high-dose period and thyroid hormone normalization in hyperthyroid patients similar to prior Graves’ disease...